Among patients with follicular #lymphoma, adding #epcoritamab to the SOC combo of #lenalidomide plus #rituximab outperformed lenalidomide plus rituximab alone, resulting in ORRs of 95% vs. 79%, as well as a lower risk of disease progression or death: https://ow.ly/652R50YrQeT
#HemeSky #MedSky

Epcoritamab Improves PFS Without OS Gain in Relapsed or Refractory DLBCL Epcoritamab significantly improved progression-free survival vs investigator’s choice in relapsed and refractory DLBCL.

#Epcoritamab improved progression-free survival (#PFS) compared with investigator’s choice chemoimmunotherapy in adults with relapsed or refractory (R/R) #DLBCL, although overall survival was not significantly different.

Read more: https://bit.ly/4qclfxv

#MedSky #RareDisease

AbbVie Shares Promising Phase 3 Data for Epcoritamab in DLBCL Patients AbbVie recently released encouraging topline results from the Phase 3 EPCORE DLBCL-1 trial for epcoritamab, targeting relapsed/refractory DLBCL patients, indicating improvements in patient outcomes.

AbbVie Shares Promising Phase 3 Data for Epcoritamab in DLBCL Patients #USA #Epcoritamab #AbbVie #North_Chicago #DLBCL

A phase 3 trial led by MSK’s Dr. Lorenzo Falchi found that adding #epcoritamab to #rituximab + #lenalidomide significantly improves outcomes for people with follicular lymphoma. Epcoritamab received FDA approval based on these findings. #ASH25

Learn more: www.mskcc.org/news/new-tri...

AbbVie Secures FDA Approval for Epcoritamab in Combination Therapy for Relapsed Follicular Lymphoma AbbVie has announced that their drug Epcoritamab in combination with rituximab and lenalidomide has received FDA approval for treating relapsed follicular lymphoma, showing significant results.

AbbVie Secures FDA Approval for Epcoritamab in Combination Therapy for Relapsed Follicular Lymphoma #United_States #Epcoritamab #North_Chicago #Rituximab #Lenalidomide

AbbVie Shares Promising Phase 2 Results for Epcoritamab Treatment in Outpatients with DLBCL AbbVie has provided updated findings from the EPCORE NHL-6 study, showcasing the potential for outpatient administration of Epcoritamab in DLBCL treatment.

AbbVie Shares Promising Phase 2 Results for Epcoritamab Treatment in Outpatients with DLBCL #USA #Epcoritamab #AbbVie #North_Chicago #DLBCL

Japan regulatory body approves epcoritamab for relapsed or refractory follicular lymphoma - SOHO Insider The Japan Ministry of Health, Labour and Welfare has approved epcoritamab (Epkinly) as a treatment for adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone at least t...

Japan regulatory body approves #epcoritamab for relapsed or refractory #FL

sohoinsider.com/lymphoma/jap...

Pharmaceutical Benefits Scheme (PBS) | PBAC Outcomes See also

Good news for patients with #DLBCL Diffuse large B-cell #lymphoma that #epcoritamab has received a positive funding recommendation from the PBAC in Australia. #lymsm 2L Axi-Cel this week, bispecifics in the 3L soon, it seems. Good news on a Friday. #lymsm

New Clinical Trial Results Show Epcoritamab's Effectiveness in Treating Diffuse Large B-Cell Lymphoma AbbVie's latest findings reveal impressive responses to Epcoritamab in treating patients with Diffuse Large B-Cell Lymphoma, both alone and in combination with other therapies.

New Clinical Trial Results Show Epcoritamab's Effectiveness in Treating Diffuse Large B-Cell Lymphoma #United_States #Epcoritamab #AbbVie #North_Chicago #DLBCL

Epcoritamab Therapy Demonstrates Promising Outcomes for Follicular Lymphoma in Clinical Trials Recent clinical trial results reveal that the investigational treatment epcoritamab shows a high response rate for follicular lymphoma, setting a new potential standard for therapy.

Epcoritamab Therapy Demonstrates Promising Outcomes for Follicular Lymphoma in Clinical Trials #United_States #Follicular_Lymphoma #Epcoritamab #AbbVie #North_Chicago